NASDAQ:ACADACADIA Pharmaceuticals Stock Price, Forecast & News

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACAD stock has increased by 34.7% and is now trading at $49.68. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 2 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.09. The biopharmaceutical company earned $90.07 million during the quarter, compared to analyst estimates of $90.76 million. ACADIA Pharmaceuticals had a negative net margin of 64.99% and a negative return on equity of 39.40%. The business's revenue was up 43.1% on a year-over-year basis. During the same period last year, the company earned ($0.59) EPS. View ACADIA Pharmaceuticals' earnings history.

ACADIA Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $420-450 million, compared to the consensus revenue estimate of $449.8 million.

17 analysts have issued 1-year price targets for ACADIA Pharmaceuticals' shares. Their forecasts range from $31.00 to $72.00. On average, they expect ACADIA Pharmaceuticals' stock price to reach $55.71 in the next year. This suggests a possible upside of 12.1% from the stock's current price. View analysts' price targets for ACADIA Pharmaceuticals.

News headlines about ACAD stock have been trending very negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ACADIA Pharmaceuticals earned a coverage optimism score of -3.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutACADIA Pharmaceuticals.

Some companies that are related to ACADIA Pharmaceuticals include Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Beigene (BGNE), Catalent (CTLT) and Sarepta Therapeutics (SRPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), Sarepta Therapeutics (SRPT), Celgene (CELG), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP), Netflix (NFLX), Omeros (OMER) and Citigroup (C).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.53%), State Street Corp (2.59%), Nuveen Asset Management LLC (1.29%), Geode Capital Management LLC (1.11%), Janus Henderson Group PLC (0.96%) and First Trust Advisors LP (0.92%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends for ACADIA Pharmaceuticals.

ACAD stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, Morgan Stanley, Sphera Funds Management LTD., Nuveen Asset Management LLC, UBS Group AG, Squarepoint Ops LLC, and BlackRock Inc.. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, and Stephen Davis. View insider buying and selling activity for ACADIA Pharmaceuticals.

ACAD stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Frontier Capital Management Co. LLC, Rock Springs Capital Management LP, Pictet Asset Management Ltd., Rice Hall James & Associates LLC, Wellington Management Group LLP, MERIAN GLOBAL INVESTORS UK Ltd, and Kornitzer Capital Management Inc. KS. View insider buying and selling activity for ACADIA Pharmaceuticals.

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACAD stock can currently be purchased for approximately $49.68.

ACADIA Pharmaceuticals has a market capitalization of $7.74 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. ACADIA Pharmaceuticals employs 465 workers across the globe.

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]